Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05139017
Title A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

diffuse large B-cell lymphoma


Bendamustine + Rituximab + VLS-101

Gemcitabine + Oxaliplatin + Rituximab + VLS-101

Bendamustine + Rituximab

Gemcitabine + Oxaliplatin + Rituximab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA

No variant requirements are available.